ORCID as entered in ROS
https://orcid.org/0000-0002-4257-7620
Scheduled Maintenance Notice
Please note that Researcher Profiles will be undergoing scheduled maintenance on Wednesday 7th Oct, from 8:00am to 9:00am. During this time, the Researcher Profiles system will be unavailable. We apologise for any inconvenience and appreciate your understanding.
Select Publications
Conference Papers
, 2025, 'Risk of CKD Progression in a Real-World Population Eligible for the ZENITH-High Proteinuria Trial', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, TX, Houston, presented at
, 2025, '1971-LB: Impact of Semaglutide on Kidney, Cardiovascular, and Mortality Outcomes by Baseline BMI and Weight Loss in People with T2D and CKD—Data from the FLOW Trial', in Diabetes, American Diabetes Association, http://dx.doi.org/10.2337/db25-1971-lb
, 2025, 'PATIENT BASELINE CHARACTERISTICS IN THE ONGOING PHASE 3 VISIONARY TRIAL: A RANDOMIZED, PLACEBO-CONTROLLED STUDY OF SIBEPRENLIMAB FOR IMMUNOGLOBULIN A NEPHROPATHY', in AMERICAN JOURNAL OF KIDNEY DISEASES, W B SAUNDERS CO-ELSEVIER INC
, 2024, 'Benefits of Semaglutide on Chronic Kidney Disease Outcomes by Cardiovascular Status or Risk in the FLOW trial', in CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, pp. E746 - E746, presented at
, 2024, 'Kidney, cardiovascular and all-cause mortality outcomes of semaglutide with and without baseline MRA use in type 2 diabetes and CKD: a FLOW trial analysis', in DIABETOLOGIA, SPRINGER, SPAIN, Madrid, pp. S519 - S519, presented at
, 2023, 'Long-Term Safety of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in CKD: A Systematic Review and Meta-Analysis of Randomized Trials', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, LIPPINCOTT WILLIAMS & WILKINS, PA, Philadelphia, pp. 367 - 367, presented at
, 2023, 'A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF BION-1301 IN ADULTS WITH IGA NEPHROPATHY', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, ITALY, Milan, pp. I398 - I399, presented at
, 2023, 'HEART FAILURE IN ASCEND-ND AND ASCEND-D', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, ITALY, Milan, pp. I453 - I455, presented at
, 2023, 'Design and Baseline Characteristics of the FIND-CKD Trial: Efficacy of Finerenone on Kidney Disease Progression in People with Non-Diabetic CKD', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. 678 - 678
, 2023, 'External Validation of a Machine Learning Model for Progression of CKD in the CREDENCE and CANVAS Trials', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. 418 - 419
, 2023, 'LONG-TERM SAFETY OF HYPOXIA INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITORS IN CHRONIC KIDNEY DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS', in NEPHROLOGY, WILEY, pp. 12 - 12
, 2023, 'Long-Term Safety of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in CKD: A Systematic Review and Meta-Analysis of Randomized Trials', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. 367 - 367
, 2023, 'Pivotal Results of the Phase 3 PROTECT Trial of Sparsentan (SPAR) vs. Irbesartan (IRB) in Patients with Immunoglobulin A Nephropathy (IgAN)', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. B1 - B1
, 2023, 'The Prevalence of CKD in Australian Primary Care: Analysis of a National General Practice Dataset', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. 373 - 373
, 2023, 'Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: insights from the CANVAS Program and CREDENCE trial', in EUROPEAN JOURNAL OF HEART FAILURE, WILEY, pp. 177 - 178
, 2022, 'Assessment Of Associations Between Hypoglycemia And Cardiovascular Outcomes In The Randomized CARMELINA And CAROLINA Trials Of The Antihyperglycemic Medication Linagliptin', in CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at
, 2022, 'Interleukin-6 and cardiovascular outcome in patients with type 2 diabetes: new insights from CANVAS', in DIABETOLOGIA, SPRINGER, SWEDEN, Stockholm, pp. S282 - S282, presented at
, 2022, 'BASELINE CHARACTERISTICS OF THE FLOW TRIAL POPULATION: KIDNEY OUTCOMES TRIAL WITH ONCE-WEEKLY SEMAGLUTIDE IN PEOPLE WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, FRANCE, Paris, pp. I893 - I894, presented at
, 2022, 'A Phase 2b Randomized Controlled Trial of Selonsertib in Moderate to Severe Diabetic Kidney Disease (MOSAIC)', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. 28 - 28
, 2022, 'A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Patients With IgA Nephropathy', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. 799 - 799
, 2022, 'Baseline cardiovascular risk in subjects with type 2 diabetes and chronic kidney disease from the FLOW trial', in EUROPEAN HEART JOURNAL, OXFORD UNIV PRESS, pp. 2617 - 2617
, 2022, 'Causes of death in patients with chronic kidney disease: insights from the ASCEND-D and ASCEND-ND cardiovascular outcomes trials', in EUROPEAN HEART JOURNAL, OXFORD UNIV PRESS, pp. 1053 - 1053
, 2022, 'Differing approaches to analyse on-treatment cardiovascular events comparing daprodustat with darbepoetin: results from the ASCEND-ND trial', in EUROPEAN HEART JOURNAL, OXFORD UNIV PRESS, pp. 2621 - 2621
, 2022, 'Effect of Canagliflozin on Markers of Hepatic Steatosis and Fibrosis in Patients With Type 2 Diabetes and CKD', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. 673 - 674
, 2022, 'Effect of Iptacopan on Proteinuria and Complement Biomarkers Over Time in IgA Nephropathy', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. 33 - 34
, 2022, 'Gene Polymorphism in Organic Anion Transporters Determine the Long-Term Efficacy and Safety of Atrasentan in Patients With Type 2 Diabetes and CKD', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. 116 - 116
, 2022, 'Lower Glomerular Filtration Rate and Higher Albuminuria Are Associated With Incident Atrial Fibrillation: A Systematic Review and Meta-Analysis', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. 297 - 298
, 2022, 'On-Treatment Cancer Safety Events With Daprodustat vs. Erythropoiesis-Stimulating Agents: Post Hoc Analyses of ASCEND-ND and ASCEND-D', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. 631 - 631
, 2021, 'Urate-lowering Therapy for Prevention of Gout: Prespecified Analyses from the CKD-FIX Trial', in ARTHRITIS & RHEUMATOLOGY, WILEY, ELECTR NETWORK, pp. 1372 - 1373, presented at
, 2021, 'Effects of canagliflozin on hyperkalaemia and serum potassium in people with diabetes and chronic kidney disease: insights from the CREDENCE trial', in EUROPEAN HEART JOURNAL, OXFORD UNIV PRESS, pp. 2647 - 2647, http://dx.doi.org/10.26190/unsworks/28409
, 2021, 'ASCEND-ND: STUDY DESIGN AND BASELINE CHARACTERISTICS', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, ELECTR NETWORK, presented at
, 2021, 'Sglt2 inhibition for ckd and cardiovascular disease in type 2 diabetes: Report of a scientific workshop sponsored by the national kidney foundation', in Diabetes, pp. 1 - 16, http://dx.doi.org/10.2337/dbi20-0040
, 2021, 'ASCEND Program: Efficacy and Safety from ASCEND-D and -ND and Overall MACE Finding', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. B2 - B3
, 2021, 'Circulating Metabolites to Predict Renal Outcomes in CANVAS Type 2 Diabetes Mellitus Population', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. 47 - 47
, 2021, 'Effects of Canagliflozin (CANA) on Kidney Outcomes: Pooled Analyses from the CANVAS Program and CREDENCE', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. 263 - 264
, 2021, 'IL-6 Inhibitor Ziltivekimab Increases Serum Hemoglobin and Iron Biomarkers in Patients with CKD Stage 3-5: A RESCUE Trial Analysis', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. 190 - 190
, 2021, 'The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A Post Hoc Analysis of the SONAR Trial', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. 728 - 728
, 2021, 'The TESTING Study: Steroids vs. Placebo in High Risk IgA Nephropathy', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. B1 - B1
, 2020, 'THE EFFECTS OF ALLOPURINOL ON THE PROGRESSION OF CHRONIC KIDNEY DISEASE ACCORDING TO BASELINE KIDNEY FUNCTION: PRE-SPECIFIED ANALYSES OF THE CKD-FIX TRIAL', in NEPHROLOGY, WILEY, pp. 60 - 60, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000592647200189&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2020, 'Renoprotection with semaglutide and liraglutide: Direct or indirect effects?', in DIABETOLOGIA, SPRINGER, ELECTR NETWORK, pp. S67 - S68, presented at
, 2020, 'Establishing Core Cardiovascular Outcome Measures for Trials in Hemodialysis: Report of an International Consensus Workshop', in American Journal of Kidney Diseases, pp. 109 - 120, http://dx.doi.org/10.1053/j.ajkd.2020.01.022
, 2020, 'EFFECTS OF SEMAGLUTIDE ON CHRONIC KIDNEY DISEASE OUTCOMES: A POST HOC POOLED ANALYSIS FROM THE SUSTAIN 6 AND PIONEER 6 TRIALS', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, ELECTR NETWORK, pp. 152 - 152, presented at
, 2020, 'REDUCTION IN THE RATE OF EGFR DECLINE WITH SEMAGLUTIDE VS PLACEBO: A POST HOC POOLED ANALYSIS OF SUSTAIN 6 AND PIONEER 6', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, ELECTR NETWORK, pp. 183 - 183, presented at
, 2020, 'Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency', in American Journal of Kidney Diseases, pp. 84 - 104, http://dx.doi.org/10.1053/j.ajkd.2019.06.009
, 2019, 'Interrelationship between hypoglycemia and CV and mortality outcomes in type 2 diabetes in the CARMELINA Trial', in DIABETES-METABOLISM RESEARCH AND REVIEWS, WILEY, PEOPLES R CHINA, Xiamen, presented at
, 2019, 'Canagliflozin Reduces Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Chronic Kidney Disease Regardless of Baseline HbA1c, Including Those With HbA1c < 7%: Results From the CREDENCE Trial', in CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, PA, Philadelphia, presented at
, 2019, 'First plus recurrent CV and hospitalization events in the CArdiovascular and Renal Microvascular outcomE study with LINAgliptin (CARMELINA) in patients with type 2 diabetes and cardiorenal disease', in EUROPEAN HEART JOURNAL, OXFORD UNIV PRESS, FRANCE, Paris, pp. 3877 - 3877, presented at
, 2018, 'Effects of the DPP-4 Inhibitor Linagliptin on Heart Failure Outcomes in Patients With Type 2 Diabetes and Cardio-Renal Disease in CARMELINA', in CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, pp. E771 - E772, presented at
, 2018, 'Canagliflozin and cardiovascular outcomes in patients with chronic kidney disease', in DIABETOLOGIA, SPRINGER, GERMANY, Berlin, pp. S39 - S39, presented at
, 2018, 'Acute Increase in Creatinine after Starting ACE Inhibitor and Vascular Events and Premature Death in Patients with Type 2 Diabetes-The ADVANCE Trial', in DIABETES, AMER DIABETES ASSOC, FL, Orlando, presented at
Filter by type
https://orcid.org/0000-0002-4257-7620